Morphic Medical Welcomes Three New Board Members

Morphic Medical has named James Reinstein, Teresa Matterelli, and John Barr to its Board of Directors.

“We are excited to strengthen and further diversify the expertise of our board with our newest members. Their proven leadership track records in growing life science companies and their extensive experience across multiple healthcare sectors including metabolic diseases,” Morphic Medical President/CEO Joe Virgilio said. “All three bring important perspectives and expertise to our company as we move towards commercialization of RESET, the first endoscopically delivered device therapy intended for patients unable to adequately control their metabolic disorders, including type 2 diabetes and obesity, and help patients restore healthy blood sugar levels and reduce weight.”
 
Reinstein is currently the president and CEO of Conformal Medical. With more than three decades of senior leadership experience, he brings expertise in strategic planning, commercial excellence, and M&A to Morphic Medical. Before joining Conformal, Reinstein was president, CEO, and board member for several other medical device and diagnostic companies including Saranas Inc., Cutera Inc., Drawbridge Health Inc., and Aptus Endosystems. Earlier in his career, Reinstein was senior vice president and chief commercial officer for Cyberonics Inc. (now LivaNova) and worked 17 years at Boston Scientific Corp., ultimately serving as vice president, Asia Region.

Reinstein earned a bachelor’s degree in business administration and marketing from the University of Georgia and executive management training from INSEAD in Fontainebleau, France. “It is an honor to be part of Morphic Medical and support their mission to treat the underlying cause of metabolic diseases, including type 2 diabetes and obesity,” he stated.
 
Mattarelli is the former chief commercial officer of Perspectum Ltd., a precision health technology company. Previously, she led the Obesity and Metabolic Health and Gynecological Health Business at Medtronic as global vice president and general manager. Before Medtronic’s acquisition of Covidien, Mattarelli held several senior roles and was promoted in 2012 to vice president and general manager, Canada, for the Neurovascular, Surgical, GI, Vascular, Respiratory, Renal Care, Medical Supplies Business. Mattarelli has extensive commercial and operational experience in a cross section of industries and markets including medtech, consumer packaged goods, and transportation.

“I look forward to working with Morphic Medical and making a difference in the lives of patients suffering from metabolic diseases such as diabetes and obesity,” Mattarelli said. “Type 2 Diabetes is a significant global health concern with huge financial burden to the healthcare system, not to mention the increased risk it poses to patients for other diabetes related conditions.”
 
Barr is the former board chairman for Apollo Endosurgery, now part of Boston Scientific, and former operating partner for Altamont Capital Partners, a private equity firm. Prior, Barr served on the Board of Directors of Valeritas Holdings Inc., a medical technology company focused on diabetes treatment. Previous positions include serving as CEO of Surgical Specialties Inc., a manufacturer of surgical instruments, and president, Global Surgical, at Bausch & Lomb Holdings Incorporated, an eye health products company.

“I am looking forward to working with the Morphic Medical executive team and board as the company advances its disruptive approach to bridge the gap between pharmaceuticals and surgery by providing an alternative treatment option to help reduce HbA1c and weight,” Barr concluded. 
 
Morphic Medical has developed RESET, an endoscopically delivered device therapy which offers a non-surgical, alternative treatment for type 2 diabetes and obesity. RESET is not approved for sale in the United States and is limited by federal law to investigational use only. Founded in 2003, Morphic Medical is headquartered in Boston.